Intellia Therapeutics (NTLA) announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of hereditary angioedema (HAE).Shares of the company were up 10.8% on Jan. 22 following the announcement of the news.The global double-blind, placebo-controlled HAELO study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The key endpoint of the study is to see the change in the nu ...